These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37247475)

  • 1. Barriers and facilitators of naloxone and safe injection facility interventions to reduce opioid drug-related deaths: A qualitative analysis.
    Miller NM; Campbell C; Shorter GW
    Int J Drug Policy; 2023 Jul; 117():104049. PubMed ID: 37247475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
    Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
    Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment.
    Drainoni ML; Koppelman EA; Feldman JA; Walley AY; Mitchell PM; Ellison J; Bernstein E
    BMC Res Notes; 2016 Oct; 9(1):465. PubMed ID: 27756427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.
    Bounthavong M; Suh K; Christopher MLD; Veenstra DL; Basu A; Devine EB
    Res Social Adm Pharm; 2020 Aug; 16(8):1033-1040. PubMed ID: 31706950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
    Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
    BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "They're not doing enough.": women's experiences with opioids and naloxone in Toronto.
    Macleod ER; Tajbakhsh I; Hamilton-Wright S; Laliberte N; Wiese JL; Matheson FI
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):26. PubMed ID: 33743756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harm Reduction in the Field: First Responders' Perceptions of Opioid Overdose Interventions.
    Elswick Fockele C; Frohe T; McBride O; Perlmutter DL; Goh B; Williams G; Wettemann C; Holland N; Finegood B; Oliphant-Wells T; Williams EC; van Draanen J
    West J Emerg Med; 2024 Jul; 25(4):490-499. PubMed ID: 39028235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addiction stigma and the production of impediments to take-home naloxone uptake.
    Fomiatti R; Farrugia A; Fraser S; Dwyer R; Neale J; Strang J
    Health (London); 2022 Mar; 26(2):139-161. PubMed ID: 32529843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do naloxone-based interventions work to reduce overdose deaths: a realist review.
    Miller NM; Waterhouse-Bradley B; Campbell C; Shorter GW
    Harm Reduct J; 2022 Feb; 19(1):18. PubMed ID: 35197057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to implementation of opioid overdose prevention programs in Ohio.
    Winstanley EL; Clark A; Feinberg J; Wilder CM
    Subst Abus; 2016; 37(1):42-6. PubMed ID: 26682929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.
    Allen ST; O'Rourke A; Johnson JA; Cheatom C; Zhang Y; Delise B; Watkins K; Reich K; Reich R; Lockett C
    Ann Med; 2022 Dec; 54(1):2692-2700. PubMed ID: 36168975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legacies of the war on drugs: Next of kin of persons who died of opioid overdose and harm reduction interventions in Philadelphia.
    Uzwiak BA; Hudgins A; Pizzicato LN
    Int J Drug Policy; 2021 Nov; 97():103351. PubMed ID: 34252788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-based opioid overdose prevention programs providing naloxone - United States, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(6):101-5. PubMed ID: 22337174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.
    Grant S; Smart R
    Harm Reduct J; 2022 Jun; 19(1):64. PubMed ID: 35676719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.